

Cover Story
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—
But at FDA “Maybe” has meaningWith frustrating photo finish voting results—6-6—still on the screen, FDA's cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency's Oncologic Drugs Advisory Committee:“Well, that's the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA's Oncology Center of Excellence, who gets sarcastic sometimes.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- An opportunity for Trump: Position U.S. cancer science to lead the world